文献速递消化、代谢与肾脏急症

全民医疗体系中整合实验室检测指标对急性肾脏疾病与障碍的发病率及预后研究

Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System.
PubMed 文献 · JAMA Netw Open · 2019-04-05
一句话结论不符合AKI或CKD标准但符合AKD标准的患者,远期新发CKD、CKD进展、ESKD和死亡风险均升高,其临床重要性尚待确定。

该回顾性队列研究纳入加拿大阿尔伯塔省全民医疗体系中1109099名成人(2008年至少检测一次血肌酐),按KDIGO指南标准划分CKD、AKI及无AKI的AKD并随访至2016年6月31日(中位6.0年)。结果发现无AKI的AKD常见(无CKD者每100例检测者3.8例,有CKD者0.6例),与无肾脏疾病者相比,无AKI的AKD与新发CKD(37.4% vs 7.4%;校正sHR 3.17;95%CI 3.10-3.23)、CKD进展(49.5% vs 34.6%;校正sHR 1.38;95%CI 1.33-1.44)、ESKD(0.6% vs 0.1%;校正sHR 8.56;95%CI 7.32-10.01)及死亡(25.8% vs 7.3%;校正HR 1.42;95%CI 1.39-1.45)风险升高相关。作者认为AKD识别出许多不符合CKD或AKI标准但总体风险轻度升高的患者,其临床重要性尚待确定。

要点

  • 无AKI的AKD在无CKD人群中每100例检测者3.8例、有CKD者0.6例,提示该人群常见。
  • 无AKI的AKD与新发CKD风险升高相关:37.4% vs 7.4%,校正sHR 3.17(95%CI 3.10-3.23)。
  • 无AKI的AKD与ESKD风险升高相关:0.6% vs 0.1%,校正sHR 8.56(95%CI 7.32-10.01)。
  • 无AKI的AKD与死亡风险升高相关:25.8% vs 7.3%,校正HR 1.42(95%CI 1.39-1.45)。
  • 作者结论:AKD识别出不符合CKD或AKI标准但总体风险轻度升高的患者,临床重要性尚待确定。

适用人群与场景

  • 加拿大阿尔伯塔省全民医疗体系中所有无终末期肾病(ESKD)的成人居民,2008年1月1日至12月31日期间在社区或医院至少检测过一次血清肌酐。

诊断标准与关键阈值

  • 采用KDIGO指南基于血清肌酐、估算肾小球滤过率和白蛋白尿的CKD、AKI、AKD定义划分患者。
  • AKD定义包含AKI,本研究重点为无AKI的AKD(伴或不伴CKD)。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量1109099名成人,平均(SD)年龄52.3(17.6)岁,43.0%为男性。
  • 随访:中位(四分位距)6.0(5.7-6.3)年,最长8年(研究终点2016年6月31日)。
  • 无AKI的AKD发生率:无CKD者每100例检测者3.8例,有CKD者0.6例。
  • 新发CKD:无AKI的AKD组37.4% vs 无肾脏疾病组7.4%,校正sHR 3.17(95%CI 3.10-3.23)。
  • CKD进展:无AKI的AKD组49.5% vs 无肾脏疾病组34.6%,校正sHR 1.38(95%CI 1.33-1.44)。
  • ESKD:无AKI的AKD组0.6% vs 无肾脏疾病组0.1%,校正sHR 8.56(95%CI 7.32-10.01)。
  • 死亡:无AKI的AKD组25.8% vs 无肾脏疾病组7.3%,校正HR 1.42(95%CI 1.39-1.45)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,AKD标准识别出许多不符合CKD或AKI标准但总体风险轻度升高的患者,其临床重要性尚待确定。

指南或共识出处

  • Kidney Disease: Improving Global Outcomes(KDIGO)急性肾损伤临床实践指南(原文引用)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Abnormal measurements of kidney function or structure may be identified that do not meet criteria for acute kidney injury (AKI) or chronic kidney disease (CKD) but nonetheless may require medical attention. The Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for AKI proposed criteria for the definition of acute kidney diseases and disorders (AKD), which include AKI; however, the incidence and prognosis of AKD without AKI remain unknown.

OBJECTIVE: To characterize the incidence and outcomes of AKD without AKI, with or without CKD.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study including all adult residents in a universal health care system in Alberta, Canada, without end-stage kidney disease (ESKD) and with at least 1 serum creatinine measurement between January 1 and December 31, 2008, in a community or hospital setting. Data analysis took place in 2018.

MAIN OUTCOMES AND MEASURES: The Kidney Disease: Improving Global Outcomes guideline definitions for CKD, AKI, and AKD based on serum creatinine, estimated glomerular filtration rate, and albuminuria criteria were applied to estimate the proportion of patients with CKD, AKI, and AKD without AKI, and combinations of the conditions. Patients were followed up for up to 8 years (study end date, June 31, 2016) to characterize their risks of mortality, development of new CKD, progression of preexisting CKD, and ESKD.

RESULTS: Among 1 109 099 Alberta residents included in the cohort, the mean (SD) age was 52.3 (17.6) years, and 43.0% were male. Findings showed that AKD without AKI was common (3.8 individuals without preexisting CKD and 0.6 with preexisting CKD per 100 population tested). In Cox proportional hazards and competing risks models over a median (interquartile range) of 6.0 (5.7-6.3) years of follow-up, AKD without AKI (compared with no kidney disease) was associated with higher risks of developing new CKD (37.4% vs 7.4%%; adjusted sub-hazard ratio [sHR], 3.17; 95% CI, 3.10-3.23), progression of preexisting CKD (49.5% vs 34.6%; adjusted sHR, 1.38; 95% CI, 1.33-1.44), ESKD (0.6% vs 0.1%; adjusted sHR, 8.56; 95% CI, 7.32-10.01), and death (25.8% vs 7.3%; adjusted hazard ratio, 1.42; 95% CI, 1.39-1.45).

CONCLUSIONS AND RELEVANCE: Criteria for AKD identified many patients who did not meet the criteria for CKD or AKI but had overall modestly increased risks of incident and progressive CKD, ESKD, and death. The clinical importance of AKD remains to be determined.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. James MT, Levey AS, Tonelli M, et al. Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System. JAMA Netw Open. 2019. PMID: 30951162. doi:10.1001/jamanetworkopen.2019.1795

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。